The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis. Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis. Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV). * An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography. Estimated duration: 2h. * A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second electroencephalography will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs). This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
Sleep hygiene and safety education session
Centre hospitalier universitaire vaudois (CHUV)
Lausanne, Canton of Vaud, Switzerland
RECRUITINGChange, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
Parasomniac episodes scored on infrared home video recording
Time frame: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
Duration of parasomniac episodes
Using home video recording
Time frame: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
Rate of confusional arousals, sleepwalking and sleep terrors episodes
Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording
Time frame: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
Incidence of emotions related to parasomniac episodes
Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?)
Time frame: Through study duration, an average of 9 weeks
Quality of life score
Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life.
Time frame: At Day 0, Week 11 and Week 18
Anxiety and depression scores
Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score \>8 denotes anxiety or depression.
Time frame: At Day 0 and Week 11
Traumatic events score
Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score.
Time frame: At Day 0
Fatigue score
Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score \>22 denotes excessive fatigue.
Time frame: At Week 2, Week 11 and Week 18
Sleepiness score
Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness.
Time frame: At Week 2, Week 11 and Week 18
Sleep quality score
Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances.
Time frame: At Week 2, Week 11 and Week 18
Severity of arousal disorders score
Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders.
Time frame: At Week 2, Week 11 and Week 18
Circadian typology score
Using a standardized questionnaire: Horne \& Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness.
Time frame: At Week 2, Week 11 and Week 18
Changes in imagery processes
Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®.
Time frame: At Day 0 and Week 11
Sleep eye movements
Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
Sleep muscles activity
Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1®
Time frame: At Week 11 (optional)
Sleep cardiac activity
Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
Sleep oxygen saturation
Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
Sleep airflow
Using sleep airflow measures with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
Sleep respiratory efforts
Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
Snoring
Using snoring measures with Titanium, Embla®, NOX-A1®.
Time frame: At Week 11 (optional)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.